安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Akero Therapeutics, Inc. (AKRO) - Yahoo Finance
Find the latest Akero Therapeutics, Inc (AKRO) stock quote, history, news and other vital information to help you with your stock trading and investing
- Investors - Akero Therapeutics, Inc.
Akero Therapeutics is a clinical stage biopharmaceutical company focused on delivering transformational medicines to patients with high unmet medical need Our current focus is on advancing our lead program efruxifermin (EFX) to provide a powerful new treatment for patients with MASH, a disease for which there are few effective treatment options
- Akero Therapeutics Announces Initiation of Phase 3 - GlobeNewswire
SYNCHRONY Outcomes, a global, randomized, placebo-controlled, 2-cohort, Phase 3 trial, is actively recruiting patients with compensated cirrhosis (F4) due to MASH to receive weekly injections of
- Akero - Fatty Liver Foundation
Akero Therapeutics has positioned EFX as its lead drug candidate for the treatment of NASH, highlighting its potential to address the multifaceted nature of the disease by improving liver health, insulin sensitivity, lipid profiles, and reducing body weight [2]
- Akero soars as drug shows it reverses scarring in liver disease . . .
Akero Therapeutics shares gained 117% in early trading on Monday, after its lead drug showed it can help patients with a type of liver disease to reverse scarring of the organ without worsening
- Akero drug reverses liver scarring in study of severe MASH patients - STAT
Akero Therapeutics reported Monday strong results from a nearly two-year, placebo-controlled study showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused by the
|
|
|